Prostate Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
Targeting Occult Cancer Cells in High-risk Prostate Cancer Patients
(Posted: 09/09/2008) - In this trial, prostate cancer patients classified as having a high risk of recurrence will be randomly assigned to undergo a course of neoadjuvant therapy consisting of chemotherapy and anti-androgen therapy or proceed directly to surgery.
Cilengitide for PSA-Only Progressive Prostate Cancer
(Posted: 03/27/2007, Updated: 06/17/2008) - In this trial, men with prostate cancer that is progressing, as indicated by a rising PSA level, despite antiandrogen therapy will be treated with a drug called cilengitide, which blocks receptor proteins that help prostate cancer grow and spread.
Cediranib for Androgen-Independent Prostate Cancer
(Posted: 04/29/2008) - In this trial, men with metastatic, androgen-independent prostate cancer whose cancer has continued to progress on docetaxel will take oral cediranib daily.
Bevacizumab for Hormone-Refractory Prostate Cancer
(Posted: 09/05/2006, Updated: 12/26/2007) - In this trial, men with hormone-refractory prostate cancer that has spread (metastasized) will receive standard chemotherapy with the drugs docetaxel and prednisone. Half of the participants will be randomly assigned to additionally receive treatment with a monoclonal antibody called bevacizumab.
Comparing Radiation Therapies for Prostate Cancer
(Posted: 06/26/2007) - In this trial, men with favorable-risk, localized prostate cancer will be randomly assigned to receive conventionally fractionated radiation therapy over the course of about eight weeks (41 daily treatments) or hypofractionated radiotherapy over a five-and-a-half week period (28 daily treatments).
(Posted: 09/09/2008) - In this trial, prostate cancer patients classified as having a high risk of recurrence will be randomly assigned to undergo a course of neoadjuvant therapy consisting of chemotherapy and anti-androgen therapy or proceed directly to surgery.
Cilengitide for PSA-Only Progressive Prostate Cancer
(Posted: 03/27/2007, Updated: 06/17/2008) - In this trial, men with prostate cancer that is progressing, as indicated by a rising PSA level, despite antiandrogen therapy will be treated with a drug called cilengitide, which blocks receptor proteins that help prostate cancer grow and spread.
Cediranib for Androgen-Independent Prostate Cancer
(Posted: 04/29/2008) - In this trial, men with metastatic, androgen-independent prostate cancer whose cancer has continued to progress on docetaxel will take oral cediranib daily.
Bevacizumab for Hormone-Refractory Prostate Cancer
(Posted: 09/05/2006, Updated: 12/26/2007) - In this trial, men with hormone-refractory prostate cancer that has spread (metastasized) will receive standard chemotherapy with the drugs docetaxel and prednisone. Half of the participants will be randomly assigned to additionally receive treatment with a monoclonal antibody called bevacizumab.
Comparing Radiation Therapies for Prostate Cancer
(Posted: 06/26/2007) - In this trial, men with favorable-risk, localized prostate cancer will be randomly assigned to receive conventionally fractionated radiation therapy over the course of about eight weeks (41 daily treatments) or hypofractionated radiotherapy over a five-and-a-half week period (28 daily treatments).
